Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 41 Records) |
| Query Trace: Schizophrenia and CYP1A2[original query] |
|---|
| Association of serotonin 2A receptor and lack of association of CYP1A2 gene polymorphism with tardive dyskinesia in a Turkish population. DNA and cell biology 2007 Aug 26 (8): 527-31. Boke Omer, Gunes Sezgin, Kara Nurten, Aker Servet, Sahin Ahmet Rifat, Basar Yildiz, Bagci Has |
| Correlates of response to Olanzapine in a North Indian Schizophrenia sample. Psychiatry research 2008 Dec 161 (3): 275-83. Thomas Pramod, Srivastava Vibhuti, Singh Anuradha, Mathur Priya, Nimgaonkar Vishwajit L, Lerer Bernard, Thelma B K, Deshpande Smita |
| Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients. European journal of clinical pharmacology 2010 May 66 (5): 465-74. Ghotbi Roza, Mannheimer Buster, Aklillu Eleni, Suda Akira, Bertilsson Leif, Eliasson Erik, Osby Urb |
| High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug. Journal of clinical psychopharmacology 2011 Feb 31 (1): 4-9. Skogh Elisabeth, Sjödin Ingemar, Josefsson Martin, Dahl Marja-Lii |
| Xenobiotic metabolizing and transporter genes: gene-gene interactions in schizophrenia and related disorders. Pharmacogenomics 2010 Dec 11 (12): 12. Gassó P, Mas S, Alvarez S, Trias G, Bioque M, Oliveira C, Bernardo M, Lafuente A |
| Association between CYP1A2 polymorphisms and clozapine-induced adverse reactions in patients with schizophrenia. Psychiatry research 2012 Dec 200 (2-3): 1014-7. Ferrari Marco, Bolla Emilio, Bortolaso Paola, Callegari Camilla, Poloni Nicola, Lecchini Sergio, Vender Simone, Marino Franca, Cosentino Mar |
| Candidate gene-based association study of antipsychotic-induced movement disorders in long-stay psychiatric patients: a prospective study. PloS one 2012 7 (5): e36561. Bakker P Roberto, Bakker Egbert, Amin Najaf, van Duijn Cornelia M, van Os Jim, van Harten Peter |
| The CYP1A2 -163C>A polymorphism is associated with clozapine-induced generalized tonic-clonic seizures in Brazilian schizophrenia patients. Psychiatry research 2013 Sep 209 (2): 242-5. Kohlrausch Fabiana Barzotti, Severino-Gama Clarissa, Lobato Maria Inês, Belmonte-de-Abreu Paulo, Carracedo Angel, Hutz Mara Hele |
| Pharmacogenetics of quetiapine in healthy volunteers: association with pharmacokinetics, pharmacodynamics, and adverse effects. International clinical psychopharmacology 2015 Mar 30 (2): 82-8. Cabaleiro Teresa, López-Rodríguez Rosario, Román Manuel, Ochoa Dolores, Novalbos Jesús, Borobia Alberto, Carcas Antonio, Abad-Santos Francis |
| The CYP1A2 -163C > A polymorphism is associated with super-refractory schizophrenia. Schizophrenia research 2015 Oct . de Brito Rodrigo Bernini, de Carvalho Araújo Leandro, Diniz Mateus José Abdalla, de Castro Georg Raphaela, Nabout João Carlos, Vianelo Rosana Pereira, da Silva Santos Rodrigo, da Silva Cruz Aline Helena, Ghedini Paulo Cés |
| Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 2015 Apr 16 (3): 200-5. Ivanova Svetlana A, Toshchakova Valentina A, Filipenko Maxim L, Fedorenko Olga Yu, Boyarko Evgenia G, Boiko Anastasia S, Semke Arkadiy V, Bokhan Nikolay A, Aftanas Lyubomir I, Loonen Anton J |
| CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects. Bulletin of experimental biology and medicine 2016 Mar 160 (5): 687-90. Ivanova S A, Filipenko M L, Vyalova N M, Voronina E N, Pozhidaev I V, Osmanova D Z, Ivanov M V, Fedorenko O Yu, Semke A V, Bokhan N |
| Potential Role of Patients' CYP3A-Status in Clozapine Pharmacokinetics. The international journal of neuropsychopharmacology 2017 Mar . Tóth Katalin, Csukly Gábor, Sirok Dávid, Belic Ales, Kiss Ádám, Háfra Edit, Déri Máté, Menus Ádám, Bitter István, Monostory Katal |
| Characterization CYP1A2, CYP2C9, CYP2C19 and CYP2D6 Polymorphisms Using HRMA in Psychiatry Patients with Schizophrenia and Bipolar Disease for Personalized Medicine. Combinatorial chemistry & high throughput screening 2018 6 21 (5): 374-380. Yenilmez Ebru Dundar, Tamam Lut, Karaytug Onur, Tuli Abdull |
| Response to Agomelatine Treatment is Independent of Smoking Status and Dosage: Results From the AGOPSYCH Study. Pharmacopsychiatry 2018 5 52 (3): 142-146. Englisch Susanne, Jung Hanna Sophie, Lewien Antje, Becker Anna, Nowak Ulrike, Braun Hanna, Eisenacher Sarah, Thiem Jascha, Meyer-Lindenberg Andreas, Zink Mathi |
| Cigarette smoking and heavy coffee consumption affecting response to olanzapine: The role of genetic polymorphism. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 2018 Dec 1-53. Djordjevic Natasa, Radmanovic Branimir, Cukic Jelena, Baskic Dejan, Djukic-Dejanovic Slavica, Milovanovic Dragan, Aklillu Ele |
| Implementation of pharmacogenetics in a clozapine treatment resistant patient: a case report. Pharmacogenomics 2019 8 20 (12): 871-877. Sangüesa Estela, Cirujeda Christine, Concha Julia, Padilla Pedro Pablo, Ribate María Pilar, García Cristina Bel |
| Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity. The pharmacogenomics journal 2019 Oct . Lesche Dorothea, Mostafa Sam, Everall Ian, Pantelis Christos, Bousman Chad |
| Association of the genetic polymorphisms of metabolizing enzymes, transporters, target receptors and their interactions with treatment response to olanzapine in chinese han schizophrenia patients. Psychiatry research 2020 9 293 113470. Yan Pan, Song Mingfen, Gao Bing, Wang Shuqi, Wang Shengdong, Li Jing, Fang Haihong, Wang Chengpeng, Shi Jianf |
| The CYP2C19*2 and CYP2C19*17 Polymorphisms Influence Responses to Clozapine for the Treatment of Schizophrenia. Neuropsychiatric disease and treatment 2020 16 427-432. Rodrigues-Silva Christielly, Semedo Agostinho Tavares, Neri Hiasmin Franciely da Silva, Vianello Rosana Pereira, Galaviz-Hernández Carlos, Sosa-Macías Martha, de Brito Rodrigo Bernini, Ghedini Paulo Cés |
| The association of genetic polymorphisms in CYP1A2, UGT1A4, and ABCB1 with autonomic nervous system dysfunction in schizophrenia patients treated with olanzapine. BMC psychiatry 2020 Feb 20 (1): 72. Hattori Saki, Suda Akira, Miyauchi Masatoshi, Shiraishi Yohko, Saeki Takashi, Fukushima Tadashi, Fujibayashi Mami, Tsujita Natsuki, Ishii Chie, Ishii Norio, Moritani Tosiho, Saigusa Yusuke, Kishida Iku |
| Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone. Frontiers in pharmacology 2021 8 12 711940. Soria-Chacartegui Paula, Villapalos-García Gonzalo, Zubiaur Pablo, Abad-Santos Francisco, Koller Do |
| Pharmacokinetic interactions between clozapine and valproic acid in patients with treatment-resistant schizophrenia: Does UGT polymorphism affect these drug interactions? Chemico-biological interactions 2022 Jul 364 110042. Sangüesa Estela, Cirujeda Christine, Concha Julia, Padilla Pedro Pablo, García Cristina Belén, Ribate María Pil |
Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders.
Translational psychiatry 2022 4 12 (1): 145. Okhuijsen-Pfeifer C, van der Horst M Z, Bousman C A, Lin B, van Eijk K R, Ripke S, Ayhan Y, Babaoglu M O, Bak M, Alink W, van Beek H, Beld E, Bouhuis A, Edlinger M, Erdogan I M, Ertu?rul A, Yoca G, Everall I P, Görlitz T, , Grootens K P, Gutwinski S, Hallikainen T, Jeger-Land E, de Koning M, Lähteenvuo M, Legge S E, Leucht S, Morgenroth C, Müderriso?lu A, Narang A, Pantelis C, Pardiñas A F, Oviedo-Salcedo T, Schneider-Thoma J, Schreiter S, Repo-Tiihonen E, Tuppurainen H, Veereschild M, Veerman S, de Vos M, Wagner E, Cohen D, Bogers J P A M, Walters J T R, Ya?c?o?lu A E Anil, Tiihonen J, Hasan A, Luykx J |
| The Potential Role of POR*28 and CYP1A2*F Genetic Variations and Lifestyle Factors on Clozapine and N-DesmethylClozapine Plasma Levels in Schizophrenia Patients. Expert opinion on drug metabolism & toxicology 2023 6 1-9. Merve Demirbugen Oz, Fezile Ozdemir, Kenan Can Tok, Emrah Dural, Yagmur Kir, Muge Ulusoy, Mehmet Gumustas, Bora Baskak, H Sinan Suz |
| Polygenetic risk scores and phenotypic constellations of obsessive-compulsive disorder in clozapine-treated schizophrenia. European archives of psychiatry and clinical neuroscience 2023 4 . Morgenroth Carla Lou, Kleymann Philipp, Ripke Stephan, Awasthi Swapnil, Wagner Elias, Oviedo-Salcedo Tatiana, Okhuijsen-Pfeifer Cynthia, Luykx Jurjen J, van der Horst Marte Z, Hasan Alkomiet, Bermpohl Felix, Gutwinski Stefan, Schreiter Stefan |
| CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients. Scientific reports 2023 10 13 (1): 18507. Ferenc Fekete, Ádám Menus, Katalin Tóth, Ádám Ferenc Kiss, Annamária Minus, Dávid Sirok, Aleš Beli?, Ádám Póti, Gábor Csukly, Katalin Monosto |
| The potential influence of estrogen-containing oral contraception on clozapine metabolism in a patient with known pharmacogenomic status. The mental health clinician 2024 6 14 (3): 220-223. Alyssa K Kuhn, Meina L Determan, Jessica A Wright, Eric Matey, Jonathan G Leu |
| Semi-physiological Pharmacokinetic Model of Clozapine and Norclozapine in Healthy, Non-smoking Volunteers: The Impact of Race and Genetics. CNS drugs 2024 6 . Orwa Albitar, Sabariah Noor Harun, Siti Maisharah Sheikh Ghad |
| A 6-year retrospective study of olanzapine plasma concentration inpatients with schizophrenia CYP1A2 polymorphisms in real-life settings. Heliyon 2024 11 10 (20): e39367. Yan Zhang, Lisha Sun, Yanli Su, Hui Wa |
- Page last reviewed:Feb 1, 2024
- Content source: